ask chatGPT: “theoretically, what will come after reta?”

[just some dude]

theoretically, after retatrutide, the next wave in incretin therapy could follow these directions:

• Next‑generation multi-agonists
  • Quadruple or “pan-agonists” targeting GLP‑1, GIP, glucagon, plus another metabolic pathway (e.g., amylin, PYY, or FGF21 analogs).
  • Aim: further weight loss, insulin sensitivity, and metabolic flexibility beyond tirzepatide/retatrutide.
• Oral or long-acting versions
  • Oral or monthly injectables for better adherence.
  • Could combine GLP-1/GIP agonism with small molecules for dual oral therapy.
• Tissue-targeted or personalized agonists
  • Drugs that selectively target fat, liver, or pancreas to reduce side effects and maximize efficacy.
• Combination therapies with non-incretins
  • Pairing with SGLT2 inhibitors, amylin analogs, or FGF21 analogs in one treatment.

it’s true, if in only a few years it went from sema, to tirze, to now reta, why would the progression stop anytime soon? we are already seeing such good results in terms of metabolic profile improvement, so i cant even begin to imagine the future. just compare things you’d take to diet back in the 80’s compared to now. interesting times!

 

[just some dude]

it’s true, if in only a few years it went from sema, to tirze, to now reta, why would the progression stop anytime soon? we are already seeing such good results in terms of metabolic profile improvement, so i cant even begin to imagine the future. just compare things you’d take to diet back in the 80’s compared to now. interesting times!

exactly — the pace of metabolic pharmacology has been insane.

• 1980s: mostly just diet, exercise, and sulfonylureas/metformin for diabetes, with weight loss extremely limited pharmaceutically.
• 2010s: introduction of GLP‑1 agonists like liraglutide and semaglutide, giving real appetite suppression and metabolic improvement.
• 2020s: dual/triple agonists (tirzepatide → retatrutide) actually improve insulin sensitivity, fat mass, and cardiovascular markers far beyond what lifestyle alone could do for many people.
• Next decade: likely quadruple agonists, oral long-acting combinations, tissue-targeted therapies, maybe even synergistic “metabolic cocktails” that could mimic the effect of perfect diet + exercise + hormonal balance.

so yeah — the progression probably won’t stop, it’s like we’re at the metabolic equivalent of the smartphone revolution: each generation packs more functionality, precision, and convenience.





the gap between what was possible in the 80s and now is literally night and day.

 

[dinfaralt]

good question, go patent it get the trillion dollar drug companies on their knees!!!!

 

[ThreeSix]

Thank you ChatGPT, next I want you to tell me how to synthesize this compound using household ingredients.